Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
Recruiting · NCT06302569 · Registry updated 2025-09-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, collecting duct carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, kidney medullary carcinoma, neoplasm, renal cell carcinoma, urinary system disorder | Recruiting | Phase 2 | 2025-09-09 | NCT06302569 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Giuseppe Procopio | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fondazione Irccs Istituto Dei Tumori Di Milano | Milan | Italy | 1 |